Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase

Carcinogenesis

Volumn 30, Issue 8, 2009, Pages 1298-1304

  Lapensee, Elizabeth W ^a   Schwemberger, Sandy J ^b   Lapensee, Christopher R ^a   Bahassi, El Mustapha ^a   Afton, Scott E ^b   Ben Jonathan, Nira ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GLUTATHIONE TRANSFERASE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PROLACTIN; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; GLUTATHIONE; H2AFX PROTEIN, HUMAN; HISTONE; MESSENGER RNA; VINBLASTINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA DAMAGE; ENZYME ACTIVATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; UPREGULATION; BREAST TUMOR; CELL CYCLE; CELL NUCLEUS; CYTOPLASM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL NUCLEUS; CISPLATIN; CYTOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HISTONES; HUMANS; PACLITAXEL; PROLACTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 69449103357     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp120     Document Type: Article

References (44)

1. Parkin, D. M. et al. (2006) Use of statistics to assess the global burden of breast cancer. Breast J., 12 (suppl. 1), S70-S80.
2. Decatris, M. P. et al. (2004) Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat. Rev., 30, 53-81.
3. Wang, D. et al. (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 4, 307-320.
4. Coley, H. M. (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev., 34 378-390.
5. Igney, F. H. et al. (2002) Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer, 2, 277-288.
6. Townsend, D. M. et al. (2003) The role of glutathione-S-transferase in anticancer drug resistance. Oncogene, 22, 7369-7375.
7. Rudin, C. M. et al. (2003) Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res., 63 312-318.
8. Clevenger, C. V. et al. (2003) The role of prolactin in mammary carcinoma. Endocr. Rev., 24, 1-27.
9. Ben Jonathan, N. et al. (2008) What can we learn from rodents about prolactin in humans? Endocr. Rev., 29, 1-41.
10. Ben Jonathan, N. et al. (2002) Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol. Metab., 13 245-250.
11. Goffin, V. et al. (2006) Drug insight: Prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat. Clin. Pract. Endocrinol. Metab., 2, 571-581.
12. Vonderhaar, B. K. (1998) Prolactin: The forgotten hormone of human breast cancer. Pharmacol. Ther., 79, 169-178.
13. Chen, N. Y. et al. (2002) In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Int. J. Oncol. 20, 813-818.
14. Liby, K. et al. (2003) Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res. Treat., 79, 241-252.
15. Asai-Sato, M. et al. (2005) Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Int. J. Cancer, 115, 539-544.
16. Beck, M. T. et al. (2002) Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene, 21, 5047-5055.
17. Kochendoerfer, S. K. et al. (2003) Prolactin regulation of Bcl-2 family members: Increased expression of bcl-xL but not mcl-1 or bad in Nb2-T cells. J. Endocrinol., 178, 265-273.
18. Ramamoorthy, P. et al. (2001) In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. Int. J. Oncol. 18, 25-32.
19. Howell, S. J. et al. (2008) Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res., 10 R68.
20. Perks, C. M. et al. (2004) Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer, 91 305-311.
21. LaPensee, E. W. et al. (2007) LS14 cells: A model for chemoresistance in liposarcoma. Cancer Biol. Ther., 6, 519-524.
22. Hugo, E. R. et al. (2006) LS14: A novel human adipocyte cell line that produces prolactin. Endocrinology, 147, 306-313.
23. Foster, E. R. et al. (2005) Histone H2A phosphorylation in DNA double-strand break repair. FEBS J., 272, 3231-3240.
24. Ban, N. et al. (1996) Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res., 56, 3577-3582.
25. Hsu, P. C. et al. (2006) Increasing ornithine decarboxylase activity is another way of prolactin preventing methotrexate-induced apoptosis: Crosstalk between ODC and BCL-2. Apoptosis, 11, 389-399.
26. Shaw-Bruha, C. M. et al. (1997) Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: Promoter usage and alternative mRNA splicing. Breast Cancer Res. Treat., 44, 243-253.
27. Peirce, S. K. et al. (2001) Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J. Endocrinol., 171, R1-R4.
28. Li, J. et al. (2003) The effect of age on the early disposition of doxorubicin. Cancer Chemother. Pharmacol., 51, 395-402.
29. Capri, G. et al. (1996) The role of taxanes in the treatment of breast cancer. Semin. Oncol., 23, 68-75.
30. Jones, R. B. et al. (1993) Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. Breast. Cancer. Res. Treat., 26 (suppl.), S11-S17.
31. Chakravarti, P. et al. (2005) Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells. Int. J. Oncol. 26, 509-514.
32. Okada, H. et al. (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer, 4, 592-603.
33. Battle, T. E. et al. (2002) The role of STATs in apoptosis. Curr. Mol. Med., 2, 381-392.
34. McDonald, E. S. et al. (2005) Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity. Neurobiol. Dis., 18, 305-313.
35. Ta, L. E. et al. (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology, 27, 992-1002.
36. Hinoshita, E. et al. (2000) Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res., 6, 2401-2407.
37. Siddik, Z. H. (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7265-7279.
38. Maeda, S. et al. (2004) Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci., 95, 679-684.
39. Luquita, M. G. et al. (1999) Prolactin increases the hepatic content of mu-class subunits of glutathione S-transferase in the rat. Drug Metab. Dispos., 27, 122-124.
40. Lo, H. W. et al. (2007) Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr. Opin. Pharmacol., 7, 367-374.
41. McIlwain, C. C. et al. (2006) Glutathione S-transferase polymorphisms: Cancer incidence and therapy. Oncogene, 25, 1639-1648.
42. Ambrosone, C. B. et al. (2001) Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res., 61, 7130-7135.
43. Lissoni, P. et al. (2002) A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Anticancer Res., 22, 1131-1134.
44. Gillam, M. P. et al. (2006) Advances in the treatment of prolactinomas. Endocr. Rev., 27, 485-534.